藤黄酸增强人胃癌SGC7901/DDP细胞对顺铂的敏感性

仝雷 王丽君 袁磊*

doi:10.16098/j.issn.0529-1356.2018.03.011

PDF(338 KB)

解剖学报 ›› 2018, Vol. 49 ›› Issue (3) : 337-341. DOI: 10.16098/j.issn.0529-1356.2018.03.011

肿瘤生物学

藤黄酸增强人胃癌SGC7901/DDP细胞对顺铂的敏感性

仝雷¹ 王丽君² 袁磊^3*

作者信息 +

Enhancing effect of gambogic acid on the sensibility of human gastric carcinoma SGC7901/DDP cells to cisplatin

TONG Lei¹ WANG Li-jun² YUAN Lei^3*

Author information +

文章历史 +

摘要

目的探讨藤黄酸（GA）对人胃癌SGC7901/DDP细胞顺铂敏感性的影响及其分子机制。方法采用顺铂（DDP）浓度梯度递增法构建人胃癌顺铂耐药株SGC7901/DDP细胞，采用细胞计数盒-8（CCK-8）法检测藤黄酸和顺铂对SGC7901/DDP细胞的毒性作用，采用Chou-Talalay中效分析法定量评价藤黄酸和顺铂的联合作用效果，采用流式细胞术检测细胞凋亡，采用Western blotting方法检测Bcl-2、Bax、Survivin、多药耐药相关蛋白2（MRP2）、磷酸化氨基末端蛋白激酶（p-JNK）（Thr183/Tyr185）和JNK的蛋白水平。结果藤黄酸与顺铂各自单独作用48 h的IC₅₀分别为2.94 μmmol/L和39.76 μmmol/L；当抑制率超过20%时，两者联合应用呈协同效应；藤黄酸可协同增强顺铂诱导的细胞凋亡（P<0.05），下调Survivin和MRP2蛋白水平（P<0.05），上调Bax蛋白水平（P<0.05），抑制JNK磷酸化（P<0.05）；JNK特异性抑制剂SP600125可下调MRP2蛋白水平（P<0.05）。结论藤黄酸可增强人胃癌SGC7901/DDP细胞对顺铂的敏感性，这可能与藤黄酸通过抑制JNK信号通路下调MRP2蛋白表达，以及上调Bax蛋白表达和下调Survivin蛋白表达有关。

Abstract

Objective The aim of this study is to investigate the effect of gambogic acid (GA) on the sensibility of human gastric carcinoma SGC7901/DDP cells to cisplatin (DDP) and its possible mechanism. Methods The drug-resistant SGC7901/DDP cells were established by stepwise exposure to DDP. CCK-8 assay was employed to detect the cytotoxic effect of GA and DDP on SGC7901/DDP cells, and the combined effect of GA and DDP was analyzed by Chou-Talalay method . The cell apoptosis was studied by flow cytometry. Western blotting was performed to detect the protein levels of Bcl-2, Bax, Survivin, multidrug resistance-associated protein 2 (MRP2), phosphorylated c-Jun N-terminal kinase (p-JNK) (Thr183/Tyr185) and JNK. Results The IC₅₀ values of GA and DDP were 2.94 μmol/L and 39.76 μmol/L after 48 hours treatment respectively, and the combined both drugs improved the antitumor effects on SGC7901/DDP cells. GA enhanced cisplatin-induced apoptosis (P<0.05), down-regulated Survivin and MRP2 and up-regulated Bax at the protein level (P<0.05), and inhibited phosphorylation of JNK in SGC7901/DDP cells (P<0.05). SP600125, a specific inhibitor of JNK, declined the protein level of MRP2 (P<0.05). Conclusion GA may enhance the sensibility of SGC7901/DDP cells to cisplatin by down-regulating MRP2 as a result of inactivation of the JNK signaling pathway, and up-regulating Bax and down-regulating Survivin.

导出引用

仝雷王丽君袁磊. 藤黄酸增强人胃癌SGC7901/DDP细胞对顺铂的敏感性[J]. 解剖学报. 2018, 49(3): 337-341 https://doi.org/10.16098/j.issn.0529-1356.2018.03.011

TONG Lei WANG Li-jun YUAN Lei. Enhancing effect of gambogic acid on the sensibility of human gastric carcinoma SGC7901/DDP cells to cisplatin[J]. Acta Anatomica Sinica. 2018, 49(3): 337-341 https://doi.org/10.16098/j.issn.0529-1356.2018.03.011

参考文献

［1］McLean MH, El-Omar EM. Genetics of gastric cancer［J］. Nat Rev Gastroenterol Hepatol, 2014, 11(11):664-674.

［2］Kalni?a Z, Meistere I, Kikuste I, et al. Emerging blood-based biomarkers for detection of gastric cancer［J］. World J Gastroenterol, 2015, 21(41):11636-11653.

［3］Chen XL, Chen XZ, Yang C, et al. Docetaxel, cisplatin and fluorouracil (DCF) regimen compared with non-taxane-containing palliative chemotherapy for gastric carcinoma: a systematic review and meta-analysis［J］. PLoS One, 2013, 8(4):e60320.

［4］Kashyap D, Mondal R, Tuli HS, et al. Molecular targets of gambogic acid in cancer: recent trends and advancements［J］. Tumour Biol, 2016, 37(10):12915-12925.

［5］Wang LH, Li Y, Yang SN, et al. Gambogic acid synergistically potentiates cisplatin-induced apoptosis in non-small-cell lung cancer through suppressing NF-κB and MAPK/HO-1 signalling［J］. Br J Cancer, 2014, 110(2):341-352.

［6］Zhang W, Zhou H, Yu Y, et al. Combination of gambogic acid with cisplatin enhances the antitumor effects on cisplatin-resistant lung cancer cells by downregulating MRP2 and LRP expression［J］. Onco Targets Ther, 2016, 9:3359-3368.

［7］Zhao W, Xia SQ, Zhuang JP, et al. Hypoxia-induced resistance to cisplatin-mediated apoptosis in osteosarcoma cells is reversed by gambogic acid independently of HIF-1α［J］. Mol Cell Biochem, 2016, 420(1-2):1-8.

［8］Chen PM, Cheng YW, Wu TC, et al. MnSOD overexpression confers cisplatin resistance in lung adenocarcinoma via the NF-κB/Snail/Bcl-2 pathway［J］. Free Radic Biol Med, 2015, 79:127-137.

［9］Kim CW, Lu JN, Go SI, et al. p53 restoration can overcome cisplatin resistance through inhibition of Akt as well as induction of Bax［J］. Int J Oncol, 2013, 43(5):1495-1502.

［10］Dong H, Liu G, Jiang B, et al. Overexpression of the Survivin gene in SGC7901 cell resistance to cisplatin［J］. Oncol Lett, 2014, 8(5):1953-1956.

［11］Cadoni E, Valletta E, Caddeo G, et al. Competitive reactions among glutathione, cisplatin and copper-phenanthroline complexes［J］. J Inorg Biochem, 2017, 173:126-133.

［12］Wortelboer HM, Balvers MG, Usta M, et al. Glutathione-dependent interaction of heavy metal compounds with multidrug resistance proteins MRP1 and MRP2［J］. Environ Toxicol Pharmacol, 2008, 26(1):102-108.

［13］Inoue K, Fry EA, Frazier DP. Transcription factors that interact with p53 and Mdm2［J］. Am J Transl Res, 2017, 9(3):1127-1138.

［14］Chen YJ, Chen SY, Lovel R, et al. Enhancing chemosensitivity in oral squamous cell carcinoma by lentivirus vector-mediated RNA interference targeting EGFR and MRP2［J］. Oncol Lett, 2016, 12(3):2107-2114.

［15］Zhan M, Qu Q, Wang G, et al. Let-7c sensitizes acquired cisplatin-resistant A549 cells by targeting ABCC2 and Bcl-XL［J］. Pharmazie, 2013, 68(12):955-961.

［16］Zhang W, Zhou H 1, Yu Y, et al. Combination of gambogic acid with cisplatin enhances the antitumor effects on cisplatin-resistant lung cancer cells by downregulating MRP2 and LRP expression［J］. Onco Targets Ther, 2016, 9:3359-3368.

［17］Lin YT, Liu YC, Chao CC. Inhibition of JNK and prothymosin-alpha sensitizes hepatocellular carcinoma cells to cisplatin［J］. Biochem Pharmacol, 2016, 122:80-89.

［18］Seino M, Okada M, Sakaki H, et al. Time-staggered inhibition of JNK effectively sensitizes chemoresistant ovarian cancer cells to cisplatin and paclitaxel［J］. Oncol Rep, 2016, 35(1):593-601.

［19］Lo Iacono M, Monica V, Vavalà T, et al. ATF2 contributes to cisplatin resistance in non-small cell lung cancer and celastrol induces cisplatin resensitization through inhibition of JNK/ATF2 pathway［J］. Int J Cancer, 2015, 136(11):2598-2609.

［20］Liu Y, Chen X, Gu Y. FOXM1 overexpression is associated with cisplatin resistance in non-small cell lung cancer and mediates sensitivity to cisplatin in A549 cells via the JNK/mitochondrial pathway［J］. Neoplasma, 2015, 62(1):61-71.